On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the FDA for vulvovaginal candidiasis (VVC) in adult women and girls of reproductive age.
Kathryn Wheeler PharmD, BCPS
Advertisement
Kathryn Wheeler, PharmD, BCPS, is an associate dean for academic affairs and clinical associate professor at the University of Connecticut School of Pharmacy.
Articles by Kathryn Wheeler PharmD, BCPS
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Advertisement
Latest Updated Articles
Novel antifungal treatment approved for vaginal candidiasisPublished: July 7th 2021 | Updated:
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Immune response may drive pelvic floor polypropylene mesh complications
2
Antenatal corticosteroid exposure linked to higher infection risk
3
Hormone therapy linked to higher autoimmune disease risk in postmenopausal women
4
Eugene Declercq, PhD, MBA, links maternal and infant mortality
5
